Dermatology

Yan discusses how acne care strategies have been bolstered—and complicated—by pharmacotherapy and telemedicine developments.

With multiple drug classes working toward FDA indication, a dermatologists explains his strategy for managing hidradenitis suppurativa.

The first trial observing the topical drug in children held promise for an extended indication.

The CHOP pediatric dermatology director reviews recent breakthroughs in understanding complex pathophysiology of skin diseases.

The investigator explains why he believes the PDE4 inhibitor is "as close to a perfect drug as you can hope for in seborrheic dermatitis."

In this episode of MEDcast, expert dermatologists discuss exciting advancements in systemic therapies such as JAK inhibitors, and the latest breakthroughs in topical treatments for plaque psoriasis

In this episode of MEDcast, expert dermatologists discuss exciting advancements in systemic therapies such as JAK inhibitors, and the latest breakthroughs in topical treatments for plaque psoriasis.

This data indicates that public health officials may need to implement measures to both help prevent and detect domestic violence in order to reduce the associated effects.

With a pair of novel drugs seeking FDA approval for the common skin infection, the agency stresses avoiding misleading products currently on the market.

This cross-sectional study showed an association, although lower absolute prevalence of Crohn’s disease for pediatric HS patients is reassuring for clinicians and patients alike.

An investigator argues for greater prescriber understanding and communication of real-world efficacy and safety outcomes for the latest oral JAK inhibitor approved for atopic dermatitis.

In this Q&A interview, Dr. Glick delved into the topics covered in his conference presentation on treating adults with plaque psoriasis and psoriatic arthritis.

Oral JAK-1 inhibitors upadacitinib and povorcitinib are showing significant benefit for patients with HS, and may soon be up for FDA decision.

This data indicates that to prevent aggravation of acne and the eventual scar formation, it may be necessary to treat acne from an early stage.

In this Q&A interview, Del Rosso discussed his presentation on eczema therapies, the updates he made to his conference presentations this year, as well as his outlook on future research.

Cases have increased annually; a clinician shares his strategy for remaining aggressive and diligent in prevention and management.

Secukinumab and bimekizumab may reach the market soon for the treatment of HS. What will it provide patients?

The cross-specialty collaboration between dermatologists and these fields has been a daily occurrence, as inflammation-targeting drugs and comorbid patients have brought team closer together.

Since roflumilast cream was approved by the FDA last July, one dermatology physician assistant advocates for its use as a primary medication.

The introduction of the TYK2 inhibitor is the latest advancement toward cross-specialty care with systemic agents.

Ahead of Fall Clinical Dermatology 2023 Conference for PAs & NPs, Glick discusses how the COVID-19 reshaped dermatology roles, and the value of physician assistants and nurse practitioners in the current care team.

Boni Elewski, MD, and Benjamin Kaffenberger, MD, and Carly Elston, MD, provide their recommendations for clinicians who are taking care of patients with rare dermatological disorders in the critical care setting.

Dermatological experts discuss challenges that are associated with the use of standard and emerging treatments in special patient population.

This new research indicates substantial detection of lower-risk disease among patients who are considered to be health-seeking.

These 4 treatments and their biosimilars show no significant differences, though future studies may be necessary to assess long-term efficacy and safety of biosimilars in treating psoriasis.

Andrew Blauvelt, MD, discusses switching therapies for atopic dermatitis (AD) treatment.

Andrew Blauvelt, MD, discusses upadacitinib for the treatment of atopic dermatitis (AD).

A dermatology expert discusses taking a nuanced approach to interpreting the boxed warnings for JAK inhibitor for atopic dermatitis (AD) treatment.

Andrew Blauvelt, MD, provides an overview of the significance of JAK/Stat pathway inhibition in targeting the pathophysiology of atopic dermatology (AD).

Andrew Blauvelt, MD, provides an overview of different treatment options that are available for patients with moderate to severe atopic dermatitis (AD).